Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

9342-8530 Quebec Inc DGCRF

Diagnocure Inc is a Canada based biotechnology company. It is primarily engaged in the business activity of development and commercialization of products relating to the diagnosis of cancer. The group generates its revenue from research and license agreement. The head office of the company is located in Quebec, Canada.


GREY:DGCRF - Post by User

Bullboard Posts
Post by ready2go1on Apr 27, 2010 11:54am
236 Views
Post# 17035317

Games

GamesNo action, all I see is investors waiting for news. As we already know, Diagnocure, keeps everything quiet and to make matters worse, Gen-Probe is very conservative and does not pump a product/marker. We should be very close to hearing something worth while but I am surprised by where the share price sits, I am still looking for the $1.60 range prior to news and I am surprised at the low volume. There are buyers but they continue to try to force the sellers down to their level. Nothing wrong with that, except that, I feel it brings in more selling and makes it difficult for us to hold gains. We are a blink away from the $1.40 range and it would have been nice to consolidate there.
     I posted a number of trials that will be discussed at the end of next month and I think there are at least 5-8 more. add to that news of the end of the FDA trial and we could be looking at $2.50. We need some big volume on the move to clean the slate and move on.
Bullboard Posts